|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||29.15 - 29.25|
|52 Week Range||19.20 - 29.50|
|PE Ratio (TTM)||39.50|
|Earnings Date||Nov 7, 2017 - Nov 13, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||29.56|
Onco360, the nation’s largest independent Oncology Pharmacy, announced today that it has been selected to participate in the limited distribution network for Eli Lilly and Company’s new product, VERZENIOTM , a twice daily oral cyclin-dependent kinase 4/6 inhibitor approved by the U.S.
PharMerica Corp. executives could receive millions from the company if they are terminated after the completion of its planned $1.4 billion acquisition. The so-called "golden parachute compensation" for the company's named executives could total about $27.7 million, according to a filing with the U.S. Securities and Exchange Commission. PharMerica has agreed to be acquired by a new company, Phoenix Parent Holdings Inc., which is controlled by New York-based KKR & Co. L.P., with Deerfield, Ill.-based Walgreens Boots Alliance Inc. (WBA) as a minority investor.
NEW YORK, Oct. 3, 2017 /PRNewswire/ -- Notice is hereby given that Faruqi & Faruqi, LLP has filed a class action lawsuit in the United States District Court for the District of Delaware, case No. 1:17-cv-01301, on behalf of shareholders of PharMerica Corporation ("PharMerica" or the "Company") (PMC) who have been harmed by PharMerica's and its board of directors' (the "Board") alleged violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") in connection with the proposed merger of the Company with affiliates of Kohlberg Kravis Roberts & Co. L.P. ("KKR").
Categories: Yahoo FinanceGet free summary analysis PharMerica Corp. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 592 million, Net Earnings of USD 4.70 million. Gross margins narrowed from 14.16% to 13.46% compared to the same period last year, operating (EBITDA) margins now 5.84% from 6.12%. Change in operating cash ... Read more (Read more...)
Rating Action: Moody's assigns B2 CFR to PharMerica Corporation; outlook stable. Global Credit Research- 12 Sep 2017. New York, September 12, 2017-- Moody's Investors Service today assigned a B2 Corporate ...
NEW YORK , Sept. 7, 2017 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a boutique securities firm headquartered at the Empire State Building in New York ...
The healthcare team led by James Momtazee has been very busy, with deals for PharMerica, American Medical Response and Covenant Surgical Partners, among others.
Envision Healthcare's (EVHC) increasing debt and expenses continue to hurt. Further guidance cut by the company is concerning.
LONDON, UK / ACCESSWIRE / August 4, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for PharMerica Corp. (NYSE: PMC ), following which we have published ...
Categories: Yahoo FinancePharMerica Corp. relative valuation is OVERVALUED and it has a fundamental analysis score of 47. Our analysis is based on comparing PharMerica Corp. with the following peers – Walgreens Boots Alliance Inc, CVS Health Corporation, BioScrip, Inc., Rite Aid Corporation, Kindred Healthcare, Inc., SunLink Health Systems, Inc., AmerisourceBergen Corporation and Guangzhou Baiyunshan Pharmaceutical Holdings Company ... Read more (Read more...)
Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of PharMerica Corporation stockholders concerning the proposed acquisition of the company by KKR & Co.
NEW ORLEANS , Aug. 3, 2017 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale ...
Former United States Securities and Exchange Commission attorney Willie Briscoe is investigating potential claims against the Board of Directors of PharMerica Corporation concerning the acquisition by KKR & Co.
Earnings in healthcare industry to be driven by acquisitions, branching out into ancillary businesses, new product and services, partly offset by increasing expenses.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for PharMerica Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)
The Louisville, Kentucky-based company said it had profit of 15 cents per share. Earnings, adjusted for amortization costs and costs related to mergers and acquisitions, came to 47 cents per share. The ...
NEW YORK , Aug. 2, 2017 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against PharMerica Corporation (NYSE: PMC) and its board of directors for breach of fiduciary duty concerning the ...
The Law Offices of Vincent Wong are investigating the Board of Directors of PharMerica Corporation for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to a newly formed company controlled by KKR, with minority investor Walgreens Boots Alliance, Inc.
PharMerica Corporation (NYSE:PMC) shares are skyrocketing as the company announced its plans to go private. The pharmaceutical company will be acquired by KKR & Co. L.P. Unit (NYSE:KKR) for $909.4 million in cash. Walgreens Boots Alliance (NASDAQ:WBA) is a minority investor in the deal. KKR will assume about $490 million of PharMerica’s debt.
NEW YORK, Aug. 2, 2017 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of PharMerica Corp. (PMC) ("PMC" or the "Company") in connection with the proposed acquisition of the Company by an affiliate of KKR & Co. LP (the "Affiliate"). On August 2, 2017, the Company announced a definitive agreement for the Affiliate to acquire all outstanding shares of PMC in a transaction valued at approximately $1.4 billion, inclusive of debt. Under the terms of the agreement, the Company's shareholders will receive $29.25 in cash for each PMC share they own.
NEW YORK , Aug. 2, 2017 /PRNewswire/ -- Harwood Feffer LLP ( www.hfesq.com ) is investigating potential claims against the board of directors of PharMerica Corporation ("PharMerica" or the "Company") ...
The following statement is being issued by Levi & Korsinsky, LLP: